Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.

摘要: Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality in United States. Therapeutic agents that target underlying biology this disease are necessary to improve outcomes. Angiogenesis plays a central role NSCLC tumor growth and metastases. The vascular endothelial factor pathway (VEGF) as therapeutic was recently validated NSCLC. Since then, multitude early phase clinical trials incorporate use angiogenesis inhibitors, either single or combination with cytotoxic chemotherapy, have been conducted advanced, refractory This article reviews these attention toxicity, efficacy, direction further study. data from suggest optimal anti-angiogenic is more likely standard agents, however most effective least toxicity yet be determined.